The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group
Abstract
The National Cancer Institute (NCI)‐sponsored Chronic Lymphocytic Leukemia (CLL) Working Group was convened to develop a set of standardized eligibility, response, and toxicity criteria for clinical trials. We recognized the previous efforts in 1967 published again in 1973 as the report of the Chronic Leukemia‐Myeloma Task Force [1] and 1978 of Cancer and Leukemia Group B (CALGB) [2]. We have used these reports for guidance during the current effort. Several noteworthy developments in the past few years have made it necessary to modify the previous guidelines. First, the diagnostic criteria for CLL and its clinical staging have been developed and well defined. Second, although staging systems facilitated entry of comparable and relatively homogeneous groups of patients in clinical trials, the definitions of response (CR) and partial response (PR) were not uniformly adopted from the previous guidelines in the clinical trials (Tables IA, IB); therefore, comparisons of results obtained in different studies became difficult. Third, there has been an improvement in our understanding of the immunology and biology of CLL. Finally, we are witnessing the emergence of several chemotherapy agents that promise impressive activity in CLL (e.g., 2′‐deoxycoformycin [3], fludarabine monophos‐phate [4,5]), and thereby offer the potential for improving survival time in this disease. To best identify regimens worthy of continued pursuit in large comparative trials, standardized guidelines for evaluation are essential. A number of laboratory investigations are also presented for which scientific interest is high yet relevance remains to be determined; thus, they are presented as companion studies to the clinical trials. This mechanism allows for flexibility in the testing of these questions and for additional ideas in the future without requiring modification of an entire treatment protocol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Self-citationBennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., & Sultan, C. (1989) · Journal of Clinical Pathology · doi:10.1136/jcp.42.6.567 · Cited by 694
Self-citationTsujimoto, Y., Yunis, J., Onorato-Showe, L., Erikson, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6610211 · Cited by 652
Rozman, C., Montserrat, E., Rodriguez-Fernandez, J., Ayats, R., Vallespi, T., Parody, R., Rios, A., Prados, D., Morey, M., & Gomis, F. (1984) · Blood · doi:10.1182/blood.v64.3.642.642 · Cited by 313
High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia
Semenzato, G., Foà, R., Agostini, C., Zambello, R., Trentin, L., Vinante, F., Benedetti, F. M., Chilosi, M., & Pizzolo, G. (1987) · Blood · doi:10.1182/blood.v70.2.396.396 · Cited by 116
Cited by
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationReport of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationHallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationFludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Self-citationKhouri, I. F., Keating, M., Körbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2817 · Cited by 919
Self-citationRozman, C., & Montserrat, E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331606 · Cited by 791
Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., et al. (1995) · Blood · doi:10.1182/blood.v85.6.1580.bloodjournal8561580 · Cited by 732
Cramer, S. L., Saha, A., Liu, J., Tadi, S., Tiziani, S., Yan, W., Triplett, K., Lamb, C., Alters, S. E., Rowlinson, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4232 · Cited by 538
Self-citationWierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.-A., Cortes, J., Koller, C., Beran, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.516 · Cited by 524
Self-citationOsterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Inhibition of Mitochondrial Respiration
Pelicano, H., Feng, L., Zhou, Y., Carew, J. S., Hileman, E. O., Plunkett, W., Keating, M. J., & Huang, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301546200 · Cited by 495
Self-citationThe French Cooperative Group on CLL, Johnson, S., Smith, A. G., Löffler, H., Ösby, E., Juliusson, G., Emmerich, B., Wyld, P. J., & Hiddemann, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91681-5 · Cited by 434
Coiffier, B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Fredriksen, H., van Oers, M. H. J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111781 · Cited by 387
Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., et al. (2007) · Blood · doi:10.1182/blood-2005-12-051458 · Cited by 348
Self-citationInfections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine
Anaissie, E. J., Kontoyiannis, D. P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S., & Keating, M. J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-7-199810010-00010 · Cited by 297
Self-citationMauro, F. R., Foa, R., Cerretti, R., Giannarelli, D., Coluzzi, S., Mandelli, F., & Girelli, G. (2000) · Blood · doi:10.1182/blood.v95.9.2786.009k30_2786_2792 · Cited by 295
Robertson, L., Chubb, S., Meyn, R., Story, M., Ford, R., Hittelman, W., & Plunkett, W. (1993) · Blood · doi:10.1182/blood.v81.1.143.143 · Cited by 290
Warner, J. L., & Arnason, J. E. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712458949 · Cited by 31
“In one of the pilots, Osterborg and colleagues, in Europe, evaluated the overall response rate (ORR), as defined by the 1988 NCI-WG guidelines [Cheson et al. 1988], in 29 patients who had been previously treated (not necessarily with purine analogs, including fludarabine).”
Background
Metadata
- Authors
- Cheson, B. D., Bennett, J. M., Rai, K. R., Grever, M. R., Kay, N. E., Schiffer, C. A., Oken, M. M., Keating, M. J., Boldt, D. H., Kempin, S. J., & Foon, K. A.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 1988-11
- Volume
- 29
- Issue
- 3
- Pages
- 152-163
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1968102342
- Cited by
- 390
- References
- 5
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.